

■ RESEARCH ARTICLE

Evaluating the efficacy of placental-derived allograft in managing non-healing pressure ulcers

Thomas Serena,¹ MD, Siobhan McGurk,¹ Emily King,¹ MS, Brianna Tramelli,¹ Dereck Shi,³ MS, Kristy Breisinger¹

¹SerenaGroup, Inc., Cambridge, MA 02142, USA

Correspondence: Brianna Tramelli (btramelli@serenagroups.com)

Received: 29 October 2025 | Accepted: 31 October 2025

Funding: This research was funded by Sequence LifeScience, Inc.

Keywords: Amniotic membranes | cellular, acellular and matrix-like products | wound care | pressure ulcers

Abstract

Background: Chronic wounds such as pressure ulcers (PUs) cause physical, emotional and financial strain on patients. Amniotic membranes have been demonstrated in previous studies to aid wound closure.

Methods: This study aims to examine the efficacy of cellular, acellular, and matrix-like products (CAMPs) in achieving complete closure of PUs that were not responsive to standard of care (SOC) treatment.

Results: Overall, 25 subjects with 37 pressure ulcers that had failed to heal with 6 weeks of SOC were treated with three-layer placental derived allograft (TLPA) for up to 16 weeks. Mean age was 69.3 years, 16 patients were female, and 9 were male. At baseline prior to intervention, mean wound size was 44.9cm² (SD 103.5) and three (8.1%) PUs achieved 40% or greater percent area reduction (PAR). At the end of TLPA treatment, 33 (89.2%) of PUs had a PAR of 40% or greater.

Conclusion: TLPA treatment was shown to achieve 40% or more wound area reduction in this cohort of 25 subjects with 37 PUs that had not responded to SPC. The observed rate of improvement supports further investigation of TLPA in prospective controlled studies to validate efficacy, assess time to closure, and determine cost-effectiveness for PUs.

Introduction

Chronic wounds such as pressure ulcers (PUs) impose substantial physical, emotional and financial strain on patients and healthcare systems. The development and persistence of PUs are exacerbated by multiple comorbidities: cardiovascular disease, diabetes, renal dysfunction, malnutrition, and immobility, all of which impair healing despite standard preventative and therapeutic efforts. Globally, PUs are recognized as a major component of the chronic-wound burden and pose significant strain on healthcare resources.

Advanced wound management incorporates cellular, acellular, and matrix-like products (CAMPs). These products offer multiple therapeutic benefits, including protection of the wound environment, coverage of exposed deep structures, facilitation of surgical closure, and improvements in both functional outcomes and cosmetic appearance.³ A subset of CAMPs, amniotic membranes (AMs), have been demonstrated in previous studies to aid wound closure.⁴ These biomaterials act as wound covers and are a rich source of amino acids, growth factors and other nutrients that support wound closure.⁵ AMs are relatively expensive,⁶ but the material costs are offset if AMs can improve healing in chronic wounds that have not responded to standard therapies, avoiding prolonged treatment and escalating complications.⁷

This is an open access article under the terms of the Creative Commons BY-NC-ND license, which enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

© 2025 The Author(s). International Journal of Tissue Repair

This study examined the efficacy of cellular, acellular, and matrix-like products (CAMPs) in achieving complete closure of non-healing PUs that were not responsive to standard of care (SOC) treatment.

Materials and methods Subjects and data collection

This retrospective, multicenter study included subjects treated for chronic ulcerated wounds, with enrollment initiated in September 2024 and treatments completed in January 2025. Inclusion and exclusion criteria are listed in *Table 1*. A total of 25 subjects met the study criteria and 14 subjects (56%) had multiple wounds for a total of 37 wounds. The current report is a planned analysis of wound healing progress and parameters only.

Subject data was collected by Sequence LifeScience, Inc. and was deidentified prior to review and analysis, with all subject identifiers removed from the study file. Statistics were calculated using R studio (v. 4.5 software, Austria, 2025). Categorical variables are presented as N and (percentage) and continuous variables are presented as mean (standard deviation) or median (interquartile range).

The Advarra Institutional Review Board determined that this study did not meet the criteria for human subjects research as defined by 45 CFR 46.102(f).

Study intervention and outcomes

Advanced therapy wound care treatment used three-layer placental-derived allo-graft (TLPA; Activate Matrix, Sequence LifeScience, Inc., US). After appropriate wound preparation, TLPA was applied to the wound site according to manufacturer's instructions. After documentation of wound characteristics, wounds were debrided, and any biofilm, subcutaneous tissue and exudate were removed. TLPA was then applied, with the amount of product used noted. SOC conservative therapies included instructions regarding limb elevation or use of specialized beds/chairs.

Study subjects received advanced therapy wound care treatment for up to 16 weeks, or until complete wound closure (100% area reduction) was achieved. The primary endpoint was complete wound closure of the target ulcer. Secondary endpoints were time (in days) until wound closure, percent area reduction (PAR) in wound size (as measured in cm²) compared to measurement at week 1 (initiation of advanced treatment), number of grafts used, and adverse events associated with the intervention product(s) or procedure(s). Analysis outcomes reported are wound size, PAR, and number of treatment visits.

Results

A total of 25 subjects with 37 PUs met study criteria; 9 were male, and 16 were female, with a mean age of 69.3 (21.5) years. Of the group, 14 subjects had multiple ulcers. The wounds included stage 3 (29.7%) and 4 (70.3%) PUs. The earliest reported onset date of a wound was February 2023, with the latest reported onset date of a wound was December 2024. Patients received a median of 7 (IQR 6-10) weekly applications; the mean was 8.37 (SD 3.5; range 2-16).

At baseline presentation of the wound prior to initiation of SOC, the minimum wound area was 0.36cm² and the maximum wound area was 591.36cm², with a mean of 44.9cm² (SD 103.5 cm²) During SOC treatment, three (8.1%) wounds achieved 40% or greater PAR. All patients received TLPA during advanced therapy wound care. At initiation (week 1) of advanced therapy wound care, the minimum wound area was 2cm² and the maximum wound area was 545.16cm², with a mean wound area of 42.3 (SD 94.5) cm². The mean amount of product used during advanced

TABLE 1 | Inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria
Subjects must be at least 18 years of age or older.	The potential subject's target ulcer is infected or if there is cellulitis in the surrounding skin.
The potential subject's target ulcer must have been present for a minimum of 4 weeks treated with SOC, prior to the initial screening visit.	There is evidence of osteomyelitis complicating the target ulcer.
The potential subject must have given permission to share data at the time of treatment.	The potential subject has been treated with hyperbaric oxygen therapy or a CAMP in the 30 days prior to the initial screening visit.

CAMP=Cellular acellular, or matrix-like Product, SOC=standard of care

This is an open access article under the terms of the Creative Commons BY-NC-ND license, which enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

@ 2025 The Author(s). International Journal of Tissue Repair




FIGURE 1 | Percent Area Reduction (PAR) for stage 3 and 4 pressure ulcers.

wound therapy care was 290.5cm² (SD 598.9), and the median amount of product used was 88cm² (IQR 220.4). At the end of data collection 33 (89.2%) wounds achieved greater than 40% area reduction after receiving TLPA treatment. No subjects achieved 100% PAR at or before 16 weeks of TLPA treatment. *Figure 1* shows percent area reduction (PAR) during advanced therapy wound care. Stage 3 PUs achieved a mean PAR of 75.8cm² (SD 15.1) while Stage 4 PUs achieved a mean PAR of 63.3cm² (SD 22.3).

Discussion

In the current study, 25 subjects with chronic stage 3 and 4 PUs refractory to 4-6 weeks of SOC treatment, underwent TLPA treatment for up to 16 weeks. Compared to 8.1% during SOC, at the end of the study, 89.2% of wounds had achieved ≥40% reduction in area during a median of 7 IQR (6-10) weekly applications. These findings suggest that TLPA may substantially enhance closure rates in patients with chronic PUs that did not heal with SOC. However, evidence on advanced biologic and cellular therapies for PUs remains limited compared with other chronic wound types such as diabetic foot ulcers and venous leg ulcers. Given the multifactorial pathophysiology and high recurrence rates associated with PUs, larger, randomized controlled trials are needed to validate these results.

Limitations

These results are subject to all the limitations of a retrospective, observational design. The lack of a control comparison group limits the ability to quantify the degree of improvement achieved with TLPA as what could be achieved with prolonged SOC. Potential confounding factors from comorbidities, primary diagnoses and other sources of unmeasured variance affects the generalizability of the findings.

Conclusions

TLPA treatment was shown to achieve 40% or more wound area reduction in this cohort of 25 subjects with 37 with PUs that had not responded to SOC. These findings suggest that TLPA may serve as an effective adjunctive therapy for managing chronic pressure ulcers, supporting tissue repair and reducing the burden of chronic wound management. Further randomized controlled studies are recommended to confirm these outcomes, evaluate complete closure rates, and determine patient quality of life outcomes.

Conflicts of interest

The authors declare no conflicts of interest.

Data availability statement

The data is proprietary but is available on request to the corresponding author.

Author contributions

Conceptualization, TS; methodology, TS and EK; formal analysis, EK and DS; writing—original draft preparation, TS, SM, BT and EK; writing—review and editing, TS, SM, EK DS and BT; project administration, KB. All authors have read and agreed to the published version of the manuscript.

This is an open access article under the terms of the Creative Commons BY-NC-ND license, which enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

© 2025 The Author(s). International Journal of Tissue Repair

References

- 1. Zhang S, Wei G, Han L et al. Global, regional and national burden of decubitus ulcers in 204 countries and territories from 1990 to 2021: a systematic analysis based on the global burden of disease study 2021. Front Public Health. 2025; 13:1494229. https://doi.org/10.3389/fpubh.2025.1494229
- 2. Jaul E, Barron J, Rosenzweig JP et al. An overview of co-morbidities and the development of pressure ulcers among older adults. BMC Geriatr. 2018; 18, 305. https://doi.org/10.1186/s12877-018-0997-7
- 3. Wu, Stephanie et al. Best practice for wound repair and regeneration use of cellular, acellular and matrix-like products (CAMPs). J Wound Care. 2023; 32,Sup4b: S1-S31. https://doi.org/10.12968/jowc.2023.32.Sup4b.S1
- 4. Dehghani M, Azarpira N, Karimi VM, Mossayebi H, Esfandiari E. Grafting with cryopreserved amniotic membrane versus conservative wound care in treatment of pressure ulcers: a randomized clinical trial. Bull Emerg Trauma. 2017; 5(4), 249–258. https://doi.org/10.18869/ACADPUB.BEAT.5.4.452
- 5. Lakmal K, Basnayake O, Hettiarachchi D. Systematic review on the rational use of amniotic membrane allografts in diabetic foot ulcer treatment. BMC Surg. 2021;21(1):87. https://doi.org/10.1186/s12893-021-01084-8
- Tettelbach WH, Armstrong DG, Chang TJ, et al. Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment. J Wound Care. 2022;31(Sup2):S10-S31. https://doi.org/10.12968/jowc.2022.31.Sup2.S10
- 7. Tettelbach W, Armstrong D, Niezgoda J, et al. The hidden costs of limiting access: clinical and economic risks of Medicare's future effective cellular, acellular and matrix-like products (CAMPs) Local Coverage Determination. J Wound Care. 2025;34(Sup5):S5-S14. https://doi.org/10.12968/jowc.2025.0120

This is an open access article under the terms of the Creative Commons BY-NC-ND license, which enables reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.